From: In silicotoxicology models and databases as FDA Critical Path Initiative toolkits
Drug safety issue | Description of in silico project |
---|---|
QT prolongation | FDA Critical Path Initiative Project: Building an in silico tool for screening new drugs for QT prolongation potential, using human clinical trial data |
Phospholipidosis | FDA/CDER working group on drug-induced phospholipidosis. Database and development of predictive computational models of drug-induced phospholipidosis |
Hepatotoxicity | Collaboration with FDA Office of Women's Health and Office of New Drugs Botanical Review Team in a computational human health effects study to help assess the safety of botanical extracts widely used by women in the USA to manage symptoms of the menopause |
Ecotoxicology of pharmaceuticals | Construction of ecotoxicology models to support FDA/CDER regulatory assessments on the environmental fate of pharmaceuticals |
Human-specific drug metabolite prediction | Exploratory research into utility and capability of in silico methods for predicting human drug-metabolites |
Nanotechnology | Exploratory research into use of computational methods to help evaluate physico-chemical properties of nanoparticles |